Old Web
English
Sign In
Acemap
>
authorDetail
>
Wolfram Samlowski
Wolfram Samlowski
Emory University
Refractory
Tolerability
Medicine
Internal medicine
Cancer
5
Papers
15
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (5)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Complete response of metastatic cervical adenocarcinoma treated with chemoradiotherapy followed by pembrolizumab: A case report
2021
Journal of Case Reports
Wolfram Samlowski
Mark Chang
Raul Meoz
Amin Hedayat
Show All
Source
Cite
Save
Citations (0)
220 Real-world outcomes of patients with resected stage IIIA melanoma treated with adjuvant nivolumab
2020
Journal for ImmunoTherapy of Cancer
Wolfram Samlowski
Robert Nicholas
Tayla Poretta
Andriy Moshyk
Jonathan Rajkumar
Anthony Salvatore
Brian Stwalley
Esmond D. Nwokeji
Show All
Source
Cite
Save
Citations (0)
Abstract A96: Phase 1 study of HSP90 inhibitor MPC-3100 in subjects with refractory or recurrent cancer.
2011
Molecular Cancer Therapeutics
Wolfram Samlowski
K. Papadopoulos
Anthony J. Olszanski
Kenton Zavitz
Daniel M. Cimbora
Siobhan Shawbell
Alfred H. Balch
Gary Mather
Andrew P. Beelen
Show All
Source
Cite
Save
Citations (5)
MPC-3100, a fully synthetic, orally bioavailable Hsp90 inhibitor, in cancer patients.
2010
Journal of Clinical Oncology
Margaret K. Yu
Wolfram Samlowski
Vijay Baichwal
Brita Brown
Brent A. Evans
Deane Woodland
Gary Mather
Amita Patnaik
Anthony W. Tolcher
K. Papadopoulos
Show All
Source
Cite
Save
Citations (7)
A phase II study of YM155 administered as 168 hour continuous infusion in stage IV and unresectable stage III melanoma.
2007
Molecular Cancer Therapeutics
Doru Alexandrescu
Rene Gonzales
Karl Lewis
Wolfram Samlowski
Lee Cranmer
Joseph Catlett
John Kirkwood
Eric Whitman
David H. Lawson
P. Bartels
Terry Drake
Anne Keating
Show All
Source
Cite
Save
Citations (3)
1